新型降尿酸药非布索坦的临床研究进展(4)
[19] Reza Khosravan,Brian A. Grabowski,Jing-Tao Wu,et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat,a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects[J].Clin Pharmacokinet,2006,45(8):821-841.
[20] Michael A. Becker,H. Ralph Schumacher,Jr. Robert L. Wortmann,et al.Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis&Rheumatismvol,2005,52(3):916–923.
[21] Michael A.Becker, M.D., H. Ralph Schumacher, et al.Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout [J].N Engl J Med, 2005, 353(23):916-923.
[22] Ralph H,Schumacher JR,Michael A,et al. Effects of febuxostat versus allopurinol and placebo in educing serum urate in subjects with hypemricem is and gout a 28-week,phaseⅢ randomized double-blind, parallel-group trial[J].Arthrifis Rheum,2008,59(11):1540-1548.
[23] Full Prescribing Information of Uloric[EB/OL].htqx//www.uloric.com/.
[24] Tim L,Pascal Richette.Internation Position Paper on Febuxostat[J].Clinical Rheumatology,2010(29):835-840.
(收稿日期:2013-04-23), http://www.100md.com(刘慧)
[20] Michael A. Becker,H. Ralph Schumacher,Jr. Robert L. Wortmann,et al.Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout[J].Arthritis&Rheumatismvol,2005,52(3):916–923.
[21] Michael A.Becker, M.D., H. Ralph Schumacher, et al.Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout [J].N Engl J Med, 2005, 353(23):916-923.
[22] Ralph H,Schumacher JR,Michael A,et al. Effects of febuxostat versus allopurinol and placebo in educing serum urate in subjects with hypemricem is and gout a 28-week,phaseⅢ randomized double-blind, parallel-group trial[J].Arthrifis Rheum,2008,59(11):1540-1548.
[23] Full Prescribing Information of Uloric[EB/OL].htqx//www.uloric.com/.
[24] Tim L,Pascal Richette.Internation Position Paper on Febuxostat[J].Clinical Rheumatology,2010(29):835-840.
(收稿日期:2013-04-23), http://www.100md.com(刘慧)